Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Net Margin: 2022-2025

Historic Net Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -154.17%.

  • InMed Pharmaceuticals' Net Margin fell 2150.00% to -154.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -171.13%, marking a year-over-year decrease of 3386.00%. This contributed to the annual value of -165.14% for FY2025, which is 180.00% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Net Margin stood at -154.17% for Q3 2025, which was down 12.48% from -137.07% recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Net Margin high stood at -14.56% for Q2 2023, and its period low was -1,528.88% during Q2 2022.
  • Its 3-year average for Net Margin is -157.20%, with a median of -150.47% in 2024.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Net Margin skyrocketed by 151,431bps in 2023, and later plummeted by 13,590bps in 2024.
  • Quarterly analysis of 4 years shows InMed Pharmaceuticals' Net Margin stood at -446.61% in 2022, then soared by 32,742bps to -119.19% in 2023, then slumped by 11,244bps to -231.63% in 2024, then crashed by 2,150bps to -154.17% in 2025.
  • Its last three reported values are -154.17% in Q3 2025, -137.07% for Q2 2025, and -168.12% during Q1 2025.